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Xin-guang Liu and Ming HouPrimary immune thrombocytopenia (ITP) is an organ-specific autoimmune disorder charac-0037-1963
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Seminarsterized by autoantibody-mediated enhanced platelet destruction and dysmegakaryocytopoiesis.
B cells have been demonstrated to play critical roles in the pathophysiology of ITP. B-cell-
activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are crucial cytokines
supporting survival and differentiation of B cells, and dysregulation of BAFF/APRIL is involved
in the pathogenesis of B-cell related autoimmune diseases including ITP. Currently ongoing
clinical trials using BAFF and/or APRIL-blocking agents have yielded positive results in human
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), further confirming the
pathological role of BAFF/APRIL in autoimmunity. This review will describe the function of
BAFF/APRIL and address the feasibility of BAFF/APRIL inhibition in the management of ITP.
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rimary immune thrombocytopenia (ITP) is an
immune-mediated bleeding disorder in which
platelets are opsonized by glucoprotein (GP)-
specific autoantibodies and prematurely cleared by
phagocytic cells in the reticuloendothelial system.1,2
The autoantibodies produced by autoreactive B cells
against self-antigens are considered to play a crucial
role. In addition to accelerated platelet destruction,
autoantibodies binding to megakaryocyte membranes
could interfere with megakaryocyte maturation, thus
resulting in decreased platelet production.3–5 There-
fore, ITP is generally considered as a prototype of
B-cell-mediated autoimmune disorder, although cyto-
toxic T-lymphocyte (CTL)-mediated lysis of autologous
platelets has been established as an alternative mech-
anism for platelet destruction.6,7 Based on the pivotal
roles of B-cell in ITP, B-cell–depleting therapy with
rituximab has been used as a second-line therapy for
the treatment of chronic ITP for a decade withblished by Elsevier Inc.
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Open access under CC BY-NC-ND license.relatively high efficacy and safety.8–10 Thus it is
reasonable to postulate that B-cell–targeted agents
have therapeutic potential for the management of ITP.
B-cell-activating factor (BAFF), also known as B-
lymphocyte stimulator (Blys), or tumor necrosis factor
(TNF) and apoptosis leukocyte-expressed ligand 1
(TALL-1), and its homolog, a proliferation-inducing
ligand (APRIL, or TRDL-1, TALL-2), are homotrimers
belonging to the TNF superfamily. Since identified by
several groups in 1999,11–13 BAFF and APRIL have
gradually drawn more and more attention as potent
cytokines for the modulation of B-cell differentiation
and maturation. Excessive expression of BAFF results
in the rescue of self-reactive B cells from anergy or
apoptosis, implicating an important role in the devel-
opment of autoimmunity.14 BAFF and APRIL levels
have been demonstrated to be elevated in the serum or
target organs of several kinds of autoimmune diseases
such as rheumatoid arthritis (RA),15–18 systemic lupus
erythematosus (SLE),19,20 and primary Sjogren’s syn-
drome (SS).21,22 In recent years the expression and
function of BAFF and APRIL in ITP were preliminarily
investigated by several groups.23–26 This review will
summarize the latest findings of BAFF and APRIL in the
pathophysiology of ITP, and discuss its potential as a
therapeutic target with a focus on ITP.VARIANT FORMS OF BAFF, APRIL, AND THEIR
RECEPTORS
Like many TNF ligands, BAFF and APRIL are
produced as type II transmembrane protein and thenp S89–S99 S89
Figure 1. Interaction of BAFF and APRIL with their
receptors. BAFF binds to BAFF-R, TACI with high affinity,
and to BCMA with lower affinity, while APRIL binds to
TACI, BCMA, and HSPG. BAFF–BAFF-R interaction could
induce the activation non-classical NF-kB2 pathway, or
inhibition of the nuclear translocation of PKC-d, thus the
expression of antiapoptotic Bcl-2 family members was
upregulated. TACI and BCMA could signal through the
classical NF-kB pathway to drive class switching, inflam-
matory responses, and to counteract apoptosis.
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trimers or polymeric forms such as BAFF 60-mer virus
clusters formed by oligomerization of BAFF trimers.27
BAFF is also expressed on the cell membrane either
as full length BAFF or as an alternatively spliced form
missing 57 bp (DBAFF) that is uncleavable and acts as
an inhibitor via inducing the formation of multimeric
BAFF with diminished biologic activity.28,29 APRIL is
cleaved by a furin convertase in the Golgi and is
active in a soluble form. TWE-PRIL, another active
form of APRIL, is expressed on the cell membrane as
a fusion protein consisting of the intracellular, trans-
membrane domain of TWEAK and the extracellular
domain of APRIL.30,31 In addition, biologically active
heterotrimers of BAFF and APRIL has been identified
in the sera of patients with autoimmune diseases.32,33
Up to now, other splice variants of the cytokines are
still continuing to be identified.34
BAFF and APRIL are produced by a number of cell
types, including not only monocytes, macrophages,
dendritic cells (DCs), neutrophils, basophils, stromal
cells, epithelial cells, mast cells, fibroblast-like syno-
viocytes, astrocytes, but also activated T cells and
aberrant B cells.35 BAFF binds to three different
receptors: BAFF receptor (BAFF-R), B-cell maturation
antigen (BCMA), and transmembrane activator and
calcium modulator ligand interactor (TACI). While
APRIL binds to BCMA and TACI, but not BAFF-R. In
addition, a proteoglycan specific for APRIL has been
identified (Figure 1).36
BAFF-R is widely expressed on human B-cell
subsets, including naı¨ve, memory B cells, and plasma
cells (PCs), but not on PCs from the bone marrow
(BM) or spleen. BAFF-R is also expressed on plasma
activated T cells and regulatory T cells.37 BCMA is
preferentially expressed on PCs, plasmablasts and
tonsillar germinal center B cells.38,39 TACI is
expressed in CD27þ memory B cells, tonsillar, and
BM PCs, a subset of activated CD27, non–germinal
center cells, and a small subpopulation of naı¨ve B
cells from blood and tonsils. Additionally, intracellu-
lar TACI has been found to be present in macro-
phages and migrates to the cell surface upon
activation.40 The specific receptor for APRIL, proteo-
glycans, were detected on T lymphocytes and PCs.36
The receptor diversity associated with their definite
affinity or specificity for BAFF and APRIL suggests
their sophisticated function in immune responses.THE BAFF/APRIL SYSTEM AND SELF-TOLERANCE
B-Cell Tolerance
B cells are under precise regulation to keep a
physiological dynamic balance. A variety of immune
checkpoints were identified throughout B-cell
development, maturation, and activation. A majortolerance checkpoint, also known as the central
checkpoint, occurs in bone marrow. The process is
mediated either by clone deletion or by receptor
editing wherein the BCRs of self reactive immature B
cells are given an opportunity to rearrange their
conformation via inducing the expression of the
recombination activating gene (RAG).41–45 The sec-
ond peripheral checkpoint takes place in the spleen
and circulation, where the auto-reactive B-cell clones
were deleted or anergized.46 A third checkpoint has
been described where a significant loss of self-
reactive B cells was observed between naı¨ve B
cells and IgMþ memory B cells.47 Besides the
above-mentioned critical checkpoints, other mecha-
nisms, such as CD4þ/T-cell–mediated elimination of
auto-reactive B cells through MHCII/TCR, CD40/
CD40L, and Fas/FasL interactions, also play important
roles in the maintenance of B-cell peripheral
tolerance.48–50
BAFF-R is the key receptor triggering BAFF-
mediated immune response. BAFF–BAFF-R signaling
ITP and BAFF/APRIL S91pathway plays important roles in B cell maturation,
competition and survival. The presence of BCMA or
TACI does not compensate for the loss of BAFF-R
during B-cell development. On the contrary, TACI
acts as a negative regulatory of B-cell expansion51
while BCMA shows a specified role in maintaining
the survival of some plasma cells in the bone
marrow.52 The central checkpoint is thought to be
independent of BAFF, as BAFF-deficient mice do not
disturb this step and BAFF-R is absent at the stage.53
BAFF-mediated BAFF-R signals are essential for the
modulation of B-cell peripheral checkpoint. Exces-
sive BAFF expression could cause auto-reactive B cell
clones that should normally delete at transitional
stage to be rescued and further developed to
mature.54,55 In addition, BAFF–BAFF-R interaction
proved the key resource what mature B cells com-
pete, since B cells from BAFF-R mutants failed to
proliferate and were diluted rapidly when compet-
ing with BAFF-R–sufficient B cells.56 Furthermore,
BAFF-R signaling dictates the destiny of mature B
cells, as it is indicated that the lifespan of transi-
tional, follicular and marginal zone cells extended
after exogenous BAFF administration but was
shortened in BAFF-R mutants (Figure 2).57,58 TheseFigure 2. BAFF/APRIL receptor expression in B-cell differentiat
central checkpoint is independent of BAFF, while the peripheral
Excessive BAFF could cause auto-reactive transitional B-cell clon
induce the expansion of self-reactive MZ/B1 B cells.effects involves the upregulation of several antiapop-
totic Bcl-2 family members by activation of non-
classical nuclear factor of kappa B (NF-kB2) path-
way,57,59,60 or inhibition of the nuclear transloca-
tion of the proapoptotic protein kinase Cd (PKC-d)
(Figure 1).61 Accordingly, it is reasonable to spec-
ulate that BAFF is a critical throttle for the main-
tenance of B cells either by regulating B-cell
homeostasis and lifespan, controlling the final step
of B-cell differentiation, or by altering the stringency
of autoreactive cell elimination at the transitional
checkpoints.
BAFF also plays important roles in antibody
responses. The interaction of BAFF 60-mer or
membrane BAFF with TACI is required for T-cell–
independent type II responses and T-cell–dependent
IgM responses,62–65 but IgG responses are much less
BAFF-dependent. Additionally, interaction of BAFF
with TACI is involved in germinal center responses
as BAFF-deficient mice fail to develop a proper
follicular dendritic cell (FDC) network, which results
in the formation of smaller and unstable germinals,
where class switching and somatic hypermutation
still proceed, but with diminished IgG and second
responses.66ion process and effect of BAFF on B-cell tolerance. The
checkpoints could be affected by BAFF at different steps.
es to be rescued and further developed to mature, and
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is not involved in naive B-cell selection or survival.
The role of APRIL still require further investigation as
conflicting results has been reported: (1) in APRIL/
mouse models, one showed no obvious pheno-
type,67 while the others showed impaired switching
to IgA, bigger germinal centers and increased num-
ber of effector T cells68; (2) in APRIL overexpession
or transgenic mouse models, one group demon-
strated that APRIL overexpression had no effect on
B-cell differentiation, maturation, and function,69 yet
Planelles et al reported aging APRIL transgenic mice
develop B1 B-cell lymphomas.70 Based on the recep-
tor expression patterns on activated or antigen-
experienced B-cell subsets, and the receptor avidity
for BAFF and APRIL, it is speculated that APRIL
exerted great influence in these subsets by acting
on TACI or BCMA. Being different from BAFF-R
signaling pathway, both TACI and BCMA signal
through the classical NF-kB pathway to drive class
switching, inflammatory responses, and to counter-
act apoptosis (Figure 1).27,71Impact of BAFF/APRIL on Other Leukocytes
As mentioned above, BAFF-R is also expressed by
some T cells, and activation of BAFF–BAFF-R signal-
ing pathway may drive T-cell activation, differentia-
tion into effector T cells, Bcl2 upregulation, and
interferon (IFN)-g and interleukin (IL)-17 produc-
tion.72,73 The expansion of effector T-cell subset by
excessive BAFF was dependent on the presence B
cells, and the pathophysiological process could be
explained by a model in which excess BAFF pro-
motes the survival of self-reactive B cells, which act
as antigen-presenting cells (APCs) and are efficient in
presenting antigen to naı¨ve T cells, and next BAFF-R
expression on activated T cells was upregulated,
which in turns attracts more BAFF binding and
leading to the further activation of effector T cells.74
By acting on TACI, BAFF also induces monocyte
survival, activation and differentiation into
macrophage-like cells, and promotes dendritic cells
(DCs) maturation, which subsequently drives naı¨ve
CD4þ T-cell proliferation and differentiation into
Th1 cells.40,75 Silencing BAFF expression in synovial
DCs from arthritis mice models resulted in maturing
IL-6 producing defect, thus Th17 cell differentiation
was inhibited.72 So BAFF appears to be a pro-
inflammatory cytokine by not only activating mono-
cytes and DCs, but also directly enhancing the pro-
inflammatory activity of T cells.Role of BAFF/APRIL in Autoimmunity
The BAFF/APRIL system is under subtle control to
keep B-cell homeostasis, and aberrant expression ofBAFF/APRIL is related with a series of autoimmune
diseases. Exogenous BAFF administration in mice
model would result in excessive B-cell expansion
and elevation of serum IgM and IgA.12 Mice trans-
genic for BAFF often exhibit features of immune
dysregulation characterized by B-cell hyperplasia,
hypergammaglobulinemia, appearance of circulating
autoantibodies, and immune complex.76,77 Conse-
quently, as BAFF transgenic mice age, most of them
first culminate into a disease mimicking SLE76,77 then
sialadenitis resembling SS,21 and are very prone to
develop lymphoma especially when they lack TNF.78
In accordance with that, SLE predisposing NZB/
W(F1) and MLR-lpr/lpr mouse strains or chemically-
induced autoimmune mouse models often have
elevated levels of BAFF with the onset and progres-
sion of disease.76,79 Blocking BAFF-dependent signal-
ing with BR3-Fc or TACI-Ig could significantly
attenuate the disease activity of lupus-prone NZB/
W(F1) mice, and prolong the survival of the ani-
mals,76,80 further confirming the pathogenic roles of
BAFF in autoimmunity.
In consistency with the animal model studies,
elevated levels of BAFF were found in the serum or
target organs of human patients with different auto-
immune disorders. In SLE patients, increased serum
BAFF levels were shown to be positively correlated
with anti-DNA levels, and could be predictive of the
SLE disease activity.16,19,20 Moreover, BAFF mRNA in
PBMNCs from SLE patients, which is expressed
mainly by monocytes, DCs and also by T cells under
circumstance of active SLE, is significantly upregu-
lated and correlates more closely to disease activity
than serum BAFF protein levels.20 Like SLE, SS
patients also have increased serum BAFF levels,
which were positively associated with serum auto-
antibody levels too.81
Studies of serum BAFF levels in RA still remain
controversial as both elevated and normal serum
BAFF levels were reported in RA patients.16,17 Never-
theless, BAFF levels in the synovial fluid of RA
patients have been reported consistently to be
significantly upregulated, which implies a possible
local production of BAFF in RA.17 Besides SLE, SS,
and RA, BAFF levels were also increased in a variety
of other systemic autoimmune diseases such as
systemic sclerosis,82 Wegener granulomatosis,83
myasthenia gravis,84 hepatitis C virus (HCV)-associ-
ated cryoglobulinemia,85 and coeliac disease86 as
well as in organ-specific autoimmune diseases such
as autoimmune hepatitis,87 primary biliary cirrho-
sis,88 multiple sclerosis (MS),89 bullous pemphi-
goid,90 and localized scleroderma.91
In contrast to BAFF, the roles of APRIL in auto-
immunity are less understood. An association
between APRIL gene polymorphism and SLE has
been identified, implicating it as a susceptibility gene
ITP and BAFF/APRIL S93in SLE.92 Next Koyama et al reported serum levels
of ARPIL were increased in SLE patients, and
there was a positive correlation between anti-
DNA antibodies and serum APRIL levels.93 How-
ever, Stohl et al found circulating APRIL levels
were inversely correlated with serological and
clinical activity, suggesting a protective role of
APRIL in SLE,94 so further studies are still required
to elucidate the significance of APRIL in SLE. While
in RA, APRIL was shown to be elevated both in the
serum and the synovial fluid,16,17 and APRIL mRNA
levels in the inflamed joints of RA patients were
tightly associated with the formation of germinal
centers,15 thus APRIL might play a pathogenetic
role by stimulating B cells and fibroblast-like
synoviocytes in RA.Targeting BAFF and/or APRIL in Autoimmunity
As the gradual recognition of the importance of
BAFF/APRIL to autoimmunity, it is reasonable to
speculate that BAFF/APRIL neutralization would
provide additional benefits for the treatment of
autoimmune disorders, and inhibition of BAFF/APRIL
by blocking antibodies or fusion protein of the
receptors has been successfully used in vivo in
murine models of several autoimmune diseases such
as SLE, collagen induced arthritis (CIA), multiple
sclerosis, et al. Studies in SLE-prone mice were more
instructive and intensive as several mouse strains at
different stages of the disease have been tested with
both selective and non-selective BAFF/APRIL inhib-
itors. Taking together, these studies demonstrated
that BAFF inhibition is more effective at preventing
than treating disease.95 In most SLE-prone mouse
strains, despite failure in depleting long-lived plasma
cells and modulating anti-DNA response, blockade of
BAFF and/or APRIL could still provide certain ther-
apeutic effect.76,96,97 In contrast, in the MRL/lpr
mouse model in which the extrafollicular response
was dominant, autoantibody producing plasma cells
were depleted within 1–2 weeks after TACI-Ig
administration, which was in parallel with a signifi-
cant drop in immune complex deposition.98 The
different responses to BAFF or BAFF/APRIL blockade
in these mouse strains indicate the heterogeneity of
the disease and suggest that human autoimmunity
might respond differently to BAFF and/or BAFF/
APRIL inhibition.
In human autoimmune diseases, several therapeu-
tics targeting BAFF and APRIL are being developed.
Belimumab, a fully human IgG1 monoclonal anti-
body binding specifically to the soluble form of
BAFF, could block the interaction of soluble BAFF
with its receptor, BAFF-R, BCMA, and TACI. It has
been demonstrated that Belimumab was able to
inhibit BAFF mediated proliferation of B cellsin vitro and block the exogenous recombinant
human (rh)-BAFF-mediated in vivo expansion of
B-cells.99 Atacicept, a soluble, fully human, recombi-
nant TACI-Fc molecule, could neutralize both BAFF
and APRIL as well as BAFF/APRIL heterotrimers. In
RA, results of phase II clinical trials with belimumab
and atacicept are disappointing, with approximate
30% of American College of Rheumatology (ACR) 20
responses in all belimumab groups versus 15% in the
placebo group, and no effect in atacicept
group.100,101 In contrast, a different anti-BAFF anti-
body (LY2127399) targeting both membrane and
soluble BAFF showed relatively high response rates
as TNF blockers used in RA in a phase II study.102
The discrepancy in response to the three BAFF
inhibitors in RA patients still need to be further
addressed.
Given the established results of the BAFF upregu-
lation in the brains of mice and patients with
MS,89,103 and the beneficial effect of TACI-Ig in
mouse model of MS,104 it is rather disappointing
that the condition of MS patients deteriorated after
atacicept administration, and had to be terminated in
advance in a phase II study (ClinicalTrials.gov iden-
tifier: NCT00642902).105 A phase II clinical trial of
LY2127399 has just finished (ClinicalTrials.gov iden-
tifier: NCT00882999) and the related results have
not been reported.
The results of BAFF inhibition in SLE were more
exciting.106,107 Despite the failing to meet the pri-
mary endpoints of phase II study defined by a drop
of more than three points in the SLEDAI score at
week 24, post hoc analyses of the results revealed
that the serologically active SLE (positive antinuclear
antibody [ANA] or anti-dsDNA) patients showed a
better response to belimumab therapy demonstrated
by significant drop in SLEDAI score and anti-dsDNA
level, and the response were better at 52 weeks than
at 24 weeks.108 In the following two phase III
studies using a new composite disease outcome
measure, belimumab therapy successfully met the
primary endpoint at 52 weeks, with a significant
reduction in the frequency of severe flares and in
concurrent corticosteroid dosage.109,110 Conse-
quently, belimumab was approved by the US Food
and Drug Administration for treatment of active
autoantibody-positive SLE on March 2011, providing
a new option for the management of SLE. Further-
more, phase III clinical studies of LY2127399 and
atacicept in SLE patients are still ongoing.
Several other new biologic drugs targeting
BAFF and/or APRIL are still in development,
including BAFF antagonists BR3-Fc, AMG-623,
anti-BR3 monoclonal antibody, and APRIL blocker
BCMA-Ig. Some of these have begun clinical trials
in human autoimmunity, and the results might be
well expected.
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B/T CELLS IN ITP
ITP is a well-defined organ-specific autoimmune
hematologic disease characterized by autoantibody-
mediated platelet clearance1 and dysmegakaryocyto-
poiesis,3–5 disturbed apoptosis of T-lymphocyte,111
imbalance of Th1/Th2 ratio,112 and CTL-mediated
platelet lysis.6,7 Despite the multidysfunction steps
revealed in ITP, the emergence of antiplatelet auto-
antibodies remains the critical step, and the roles of
B cells in ITP has attracted more prominence as a
result of research both in mice and humans.2,113
Recent studies have established that B-cell depletion
therapy with rituximab (anti-CD20) could signifi-
cantly induces the amelioration of the ITP by
inhibiting autoantibody production and/or by inter-
fering with other B-cell pathogenic functions,8–10,114
thus emerged as an optional therapeutic strategy for
the management of ITP.
Based on the existing research results about the
roles which the BAFF/APRIL system acts on B-cell
development, maturation, homeostasis and immuno-
globulin production, it is reasonable to speculate
that the BAFF/APRIL system might also be dysregu-
lated in B-cell immune tolerance breaking process in
ITP, and a series of studies have proved the hypoth-
esis. In 2007, Emmerich et al demonstrated for
the first time that serum BAFF levels were elevated
in active ITP patients, and immunosuppressive
reagents, such as glucocorticoids, methotrexate,
and azathioprine could suppress the expression of
BAFF to normal levels.23 Moreover, being similar to
patients with SLE115 or B cell chronic lymphocytic
leukemia,116 a polymorphic site in the BAFF pro-
moter region (871) was also observed more fre-
quently in ITP patients, and the promoter variant
was associated with increased BAFF levels in ITP
patients.23 In the following studies, several groups
have consistently confirmed the fact that both
serum/plasma and peripheral blood mononuclear
cells (PBMNCs) mRNA expression levels of BAFF
were upregulated in active ITP patients, and signifi-
cantly decreased after disease remission.24,25,117–119
Considering the important role of the spleen for the
activation of platelet-reactive B and T cell in the
pathophysiology of ITP, Zhou et al also investigated
the mRNA expression of BAFF and BAFF-R in sple-
nocyte mononuclear cells (SPMNCs), and found that
BAFF-R mRNA expression of SPMNCs was signifi-
cantly higher than that of PBMNCs in ITP, while no
statistical difference of BAFF mRNA expression was
found between PBMNCs and SPMNCs.24 Addition-
ally, another study by the same group also observed
significant elevated expression of APRIL both in
plasma and PBMNCs mRNA levels in active ITP
patients, and the elevated plasma APRIL levels werenegatively correlated to platelet counts, but no
statistical difference in its receptors BCMA or TACI
mRNA expression between ITP patients and healthy
controls,26 suggesting the involvement of APRIL in
the etiology of ITP.
Zhou et al recently showed that in vitro cultured
monocyte-derived dendritic cells (MoDCs) could
induce a higher production of BAFF after stimulation
in active ITP patients than that of healthy controls,
thus could drive more robust B-cell proliferation and
antibody production. Nevertheless, BAFF was not
the only mediator of MoDCs as BAFF-blocking
reagents could only abrogate the effect of MoDCs
to naı¨ve B cells partially, still leaving some issues
about the precise mechanism of BAFF regulation
unsettled.120 Using in vitro co-culture systems, our
group recently found that toll-like receptor 7 (TLR7),
a potent B-cell-activating mediator,121,122 could reg-
ulates MoDC-dependent B-cell responses through
BAFF in ITP patients. MoDCs stimulated with R848
(TLR7 ligand) showed significant elevation of BAFF
mRNA expression and its protein secretion in ITP
patients, thus drove autologous B cells to produce
more anti-platelet autoantibodies. Further analysis
revealed a positive correlation between MoDC
TLR7 mRNA expression and serum BAFF in
untreated ITP patients.118 Moreover, the pathogenic
roles of TLR7 and BAFF in APCs-triggered B-cell
immune responses were further confirmed in ITP
mouse models. In our recently published work, it
was demonstrated that the protein and mRNA
expression levels of TLR7 in SPMNCs, the BAFF-R
expression in PBMNCs from ITP mice were signifi-
cantly elevated, and TLR7 stimulation was related
with considerably promoted BAFF secretion,
increased platelet-associated IgG (PAIgG) produc-
tion, and enhanced platelet destruction.123 These
findings suggest that the novel TLR7/BAFF/BAFF-R
pathway was involved in APC-mediated B-cell
responses, providing novel molecular targets for
ITP therapeutic intervention.BAFF AND/OR APRIL INHIBITION FOR ITP:
PROGRESS AND CHALLENGES
The expression of BAFF and APRIL in ITP could
be affected by multiple therapeutic measures. Pre-
dnisone and high-dose dexamethasone therapy were
able to inhibit BAFF expression effectively in
patients with active ITP.23,25 For one thing, as
reported in our previous report,23 high-dose dexa-
methasone could directly downregulate the mRNA
expression of BAFF in a dose-dependent manner. For
another, corticosteroid therapy might affect BAFF
levels in an indirect manner. It has been well
established that glucocorticoids could suppress the
expression of inflammatory cytokines such as IFN-g
ITP and BAFF/APRIL S95and TNF-a,124,125 which has the potential to induce
upregulation of BAFF.126,127 Moreover, Helicobacter
pylori eradication in the responding patients with
ITP was associated with significantly inhibited serum
BAFF levels, but this phenomenon was not observed
in non-responders of ITP.119 Besides BAFF, the
increased APRIL levels in ITP could also be signifi-
cantly downregulated by glucocorticoids, intrave-
nous immunoglobulin, and even the splenectomy.26
Nevertheless, the above mentioned immunosuppres-
sive remedies in ITP are not BAFF and/or APRIL-
specific blocking reagents, and the non-specific
inhibition of BAFF and/or APRIL by these remedies
might be related with their certain adverse effects.
Consequently, some of the BAFF and/or APRIL-
targeted inhibitors are investigated for their effi-
ciency in ITP recently.
So far, among the existing BAFF and/or APRIL-
targeted biologic reagents, only belimumab has begun
a phase II clinical study in ITP (ClinicalTrials.gov
identifier: NCT01440361), and the results might help
in the development of future treatments for ITP.
Recently, our group investigated the feasibility of
restoring immune tolerance by BR3-Fc, a soluble
BAFF antagonist, in in vitro cultured PBMNCs from
active ITP patients.117 It was demonstrated in the
study that exogenous rhBAFF could not only pro-
mote the survival of CD19þ B cells and CD8þ T cells
but also increase the apoptosis of platelets and the
secretion of IFN-g. The most prominent finding was
the successful correction of the rhBAFF-mediated
effect by BR3-Fc, suggesting that blockade of BAFF
might be a promising therapeutic approach for the
management of ITP. As ITP is a heterogeneous and
complex autoimmune disorder, further clinical trials
are needed to validate the efficiency and safety of
other BAFF and/or APRIL inhibitors in ITP.CONCLUSIONS
B cells actively participate in the breaking of
immune tolerance in several aspects such as produc-
tion of self-reactive autoantibodies, secretion of
inflammatory cytokine, and antigen presentation.128
Being a typical human autoimmune disease, consid-
erable progress has been made in understanding the
pathogenic roles of B cells in ITP. Generally, there
are two main strategies of anti-B therapy. One is to
deplete B cells by anti-CD20 mAbs (rituximab)
through antibody-dependent cell-mediated cytotox-
icity (ADCC) or complement-dependent cytotoxicity
(CDC), and rituximab has proved to be of great value
in ITP, so accepted as an alternative treatment of
refractory ITP.129,130 The other is to deprive B cells
from signals for their growth and survival thus
inducing apoptosis or anergy such as BAFF-targeted
therapy mentioned above. Up to now, cleartherapeutic effects of BAFF/APRIL blockade are
evident in human autoimmunity such as RA and
SLE,102,106,107,109,110 but effects of BAFF and/or
APRIL blockade in ITP have not yet been established.
Being an essential modulator of B-cell peripheral
tolerance checkpoint, BAFF and APRIL molecules
still remain promising targets for drug design to
address unmet clinical needs.
Taken together, the elevated BAFF and APRIL
expression in ITP and their pivotal roles in cell
survival and immune regulation have drawn a lot of
attention to these molecules as potential therapeutic
targets for the management of ITP. As ITP is a
heterogeneous and complex disease, further clinical
investigation into BAFF and/or APRIL targeted ther-
apy will help to define the role of the BAFF/APRIL
system in the development and perpetuation of ITP,
as well as their place in future therapies for certain
heterogeneous patient populations.REFERENCES
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